Lyell Immunopharma, Inc.

Healthcare · Biotechnology · United States

Last price 10.83 USD (Oct 30, 2026, 2:17 PM EDT) · Market cap 265.39M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual‑targeting CD19/CD20 CAR T‑cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy random...